Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Belite Bio

Biotech & Life Sciences · San Diego, United States · Founded 2018 · IPO 2022 Unicorn

Belite Bio is a clinical-stage drug development company targeting untreatable eye diseases and metabolic diseases with its lead pipeline, Tinlarebant

Valuation
$5.87B
Market cap · May/2026

Global footprint

Where Belite Bio has talent and traffic

Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown
Web traffic by country
8.7K monthly visits
across markets
🇺🇸 United States80.5%
🇮🇳 India16.1%
🇹🇼 Taiwan11.5%
🇨🇦 Canada3.4%
Top 4 markets shown

Market sentiment

What the market is saying about Belite Bio

An AI-synthesized read of the highest-engagement posts about Belite Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Belite Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.